(SRPT) Sarepta Therapeutics - Ratings and Ratios

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company specializing in the development of RNA-targeted therapeutics, gene therapies, and other genetic modalities for rare diseases, with a strong focus on neuromuscular disorders. The company has established a leadership position in Duchenne muscular dystrophy (Duchenne), offering a portfolio of exon-skipping therapies, including EXONDYS 51 (exon 51), VYONDYS 53 (exon 53), and AMONDYS 45 (exon 45). Additionally, Sarepta has advanced ELEVIDYS, an AAV-based gene therapy for ambulatory pediatric Duchenne patients. The company is also expanding its pipeline into limb-girdle muscular dystrophies (LGMD) with SRP-9003, a gene therapy candidate. Sareptas strategic collaborations include partnerships with Roche, Arrowhead Pharmaceuticals, and Genethon, among others, to accelerate innovation and access to treatments for rare genetic diseases.

The companys financial profile reflects its commercial-stage maturity, with a market cap of $5.23 billion and a trailing P/E of 23.05, indicating investor confidence in its growth prospects. The forward P/E of 7.09 suggests expectations of significant earnings acceleration. Sareptas price-to-sales ratio of 2.75 aligns with biotechnology industry norms, while its return on equity of 15.40% underscores operational efficiency. The stock currently trades at $60.44, below its 50-day SMA of $80.60 but above its 200-day SMA of $115.49, signaling potential volatility in the near term.